Paladin Wealth LLC Has $576,000 Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Paladin Wealth LLC increased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 9.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,457 shares of the medical equipment provider’s stock after acquiring an additional 472 shares during the period. Paladin Wealth LLC’s holdings in Zimmer Biomet were worth $576,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the company. Equity Investment Corp bought a new position in shares of Zimmer Biomet in the third quarter worth about $70,104,000. Hotchkis & Wiley Capital Management LLC lifted its stake in Zimmer Biomet by 49.1% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 1,752,298 shares of the medical equipment provider’s stock valued at $189,161,000 after purchasing an additional 577,320 shares during the last quarter. Van ECK Associates Corp boosted its position in Zimmer Biomet by 12.4% in the third quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider’s stock valued at $391,239,000 after buying an additional 411,163 shares in the last quarter. Thompson Siegel & Walmsley LLC bought a new stake in shares of Zimmer Biomet during the third quarter worth $41,588,000. Finally, FMR LLC lifted its stake in shares of Zimmer Biomet by 27.6% in the 3rd quarter. FMR LLC now owns 750,336 shares of the medical equipment provider’s stock valued at $80,999,000 after acquiring an additional 162,384 shares during the last quarter. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Trading Down 0.5 %

NYSE:ZBH opened at $100.40 on Tuesday. The firm has a fifty day simple moving average of $107.34 and a two-hundred day simple moving average of $108.07. Zimmer Biomet Holdings, Inc. has a 12 month low of $99.67 and a 12 month high of $133.90. The stock has a market capitalization of $19.99 billion, a price-to-earnings ratio of 22.56, a PEG ratio of 1.83 and a beta of 1.02. The company has a current ratio of 1.91, a quick ratio of 0.70 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period last year, the business posted $2.20 earnings per share. Analysts expect that Zimmer Biomet Holdings, Inc. will post 8.25 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Monday, December 30th were issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.96%. The ex-dividend date of this dividend was Monday, December 30th. Zimmer Biomet’s dividend payout ratio is currently 21.57%.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on ZBH shares. Raymond James reduced their price objective on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a research report on Friday. Truist Financial reaffirmed a “hold” rating and issued a $113.00 price objective (down previously from $118.00) on shares of Zimmer Biomet in a research note on Monday. Stifel Nicolaus boosted their target price on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a report on Thursday, January 23rd. Royal Bank of Canada dropped their price target on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research note on Friday. Finally, Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research note on Friday. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.